

# **B-Cell Chronic Lymphocytic Leukemia Treatment -United States Market Status and Trend Report 2013-2023**

<https://marketpublishers.com/r/BFE4005F637MEN.html>

Date: March 2018

Pages: 135

Price: US\$ 3,480.00 (Single User License)

ID: BFE4005F637MEN

## **Abstracts**

### **Report Summary**

B-Cell Chronic Lymphocytic Leukemia Treatment -United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on B-Cell Chronic Lymphocytic Leukemia Treatment industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of B-Cell Chronic Lymphocytic Leukemia Treatment 2013-2017, and development forecast 2018-2023

Main market players of B-Cell Chronic Lymphocytic Leukemia Treatment in United States, with company and product introduction, position in the B-Cell Chronic Lymphocytic Leukemia Treatment market

Market status and development trend of B-Cell Chronic Lymphocytic Leukemia Treatment by types and applications

Cost and profit status of B-Cell Chronic Lymphocytic Leukemia Treatment, and marketing status

Market growth drivers and challenges

The report segments the United States B-Cell Chronic Lymphocytic Leukemia Treatment market as:

United States B-Cell Chronic Lymphocytic Leukemia Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue

and Growth Rate 2013-2023):

New England  
The Middle Atlantic  
The Midwest  
The West  
The South  
Southwest

United States B-Cell Chronic Lymphocytic Leukemia Treatment Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

AMG-319  
ATTCK-20  
IDD-002  
JNJ-64052781  
Lenalidomide  
MAT-303  
MT-3724  
Others

United States B-Cell Chronic Lymphocytic Leukemia Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Clinic  
Hospital  
Others

United States B-Cell Chronic Lymphocytic Leukemia Treatment Market: Players Segment Analysis (Company and Product introduction, B-Cell Chronic Lymphocytic Leukemia Treatment Sales Volume, Revenue, Price and Gross Margin):

AB Science SA  
Amgen Inc.  
Celgene Corporation  
Dynavax Technologies Corporation  
Eisai  
Elsalys Biotech SAS  
F. Hoffmann-La Roche Ltd.  
iDD biotech SAS  
Immunomedics, Inc.

Johnson & Johnson  
Juno Therapeutics Inc.  
Molecular Templates Inc.  
Noxxon Pharma AG

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT**

1.1 Definition of B-Cell Chronic Lymphocytic Leukemia Treatment in This Report

1.2 Commercial Types of B-Cell Chronic Lymphocytic Leukemia Treatment

1.2.1 AMG-319

1.2.2 ATTCK-20

1.2.3 IDD-002

1.2.4 JNJ-64052781

1.2.5 Lenalidomide

1.2.6 MAT-303

1.2.7 MT-3724

1.2.8 Others

1.3 Downstream Application of B-Cell Chronic Lymphocytic Leukemia Treatment

1.3.1 Clinic

1.3.2 Hospital

1.3.3 Others

1.4 Development History of B-Cell Chronic Lymphocytic Leukemia Treatment

1.5 Market Status and Trend of B-Cell Chronic Lymphocytic Leukemia Treatment

2013-2023

1.5.1 United States B-Cell Chronic Lymphocytic Leukemia Treatment Market Status and Trend 2013-2023

1.5.2 Regional B-Cell Chronic Lymphocytic Leukemia Treatment Market Status and Trend 2013-2023

### **CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS**

2.1 Market Status of B-Cell Chronic Lymphocytic Leukemia Treatment in United States 2013-2017

2.2 Consumption Market of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Regions

2.2.1 Consumption Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Regions

2.2.2 Revenue of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Regions

2.3 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Regions

2.3.1 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in New England 2013-2017

2.3.2 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in The Middle Atlantic 2013-2017

2.3.3 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in The Midwest 2013-2017

2.3.4 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in The West 2013-2017

2.3.5 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in The South 2013-2017

2.3.6 Market Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment in Southwest 2013-2017

2.4 Market Development Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in United States 2018-2023

2.4.1 Market Development Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in United States 2018-2023

2.4.2 Market Development Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment by Regions 2018-2023

## **CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Types

3.1.2 Revenue of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Types

## **CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Downstream Industry

4.2 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Major Countries

4.2.1 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in New England

4.2.2 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in The Midwest

4.2.4 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in The West

4.2.5 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in The South

4.2.6 Demand Volume of B-Cell Chronic Lymphocytic Leukemia Treatment by Downstream Industry in Southwest

4.3 Market Forecast of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT**

5.1 United States Economy Situation and Trend Overview

5.2 B-Cell Chronic Lymphocytic Leukemia Treatment Downstream Industry Situation and Trend Overview

## **CHAPTER 6 B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES**

6.1 Sales Volume of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Major Players

6.2 Revenue of B-Cell Chronic Lymphocytic Leukemia Treatment in United States by Major Players

6.3 Basic Information of B-Cell Chronic Lymphocytic Leukemia Treatment by Major Players

6.3.1 Headquarters Location and Established Time of B-Cell Chronic Lymphocytic Leukemia Treatment Major Players

6.3.2 Employees and Revenue Level of B-Cell Chronic Lymphocytic Leukemia Treatment Major Players

- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 AB Science SA
  - 7.1.1 Company profile
  - 7.1.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.1.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of AB Science SA
- 7.2 Amgen Inc.
  - 7.2.1 Company profile
  - 7.2.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.2.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Amgen Inc.
- 7.3 Celgene Corporation
  - 7.3.1 Company profile
  - 7.3.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.3.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.4 Dynavax Technologies Corporation
  - 7.4.1 Company profile
  - 7.4.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.4.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Dynavax Technologies Corporation
- 7.5 Eisai
  - 7.5.1 Company profile
  - 7.5.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.5.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Eisai
- 7.6 Elsalys Biotech SAS
  - 7.6.1 Company profile
  - 7.6.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.6.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Elsalys Biotech SAS
- 7.7 F. Hoffmann-La Roche Ltd.

- 7.7.1 Company profile
- 7.7.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
- 7.7.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
- 7.8 iDD biotech SAS
  - 7.8.1 Company profile
  - 7.8.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.8.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of iDD biotech SAS
- 7.9 Immunomedics, Inc.
  - 7.9.1 Company profile
  - 7.9.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.9.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Immunomedics, Inc.
- 7.10 Johnson & Johnson
  - 7.10.1 Company profile
  - 7.10.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.10.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.11 Juno Therapeutics Inc.
  - 7.11.1 Company profile
  - 7.11.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.11.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Juno Therapeutics Inc.
- 7.12 Molecular Templates Inc.
  - 7.12.1 Company profile
  - 7.12.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.12.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Molecular Templates Inc.
- 7.13 Noxxon Pharma AG
  - 7.13.1 Company profile
  - 7.13.2 Representative B-Cell Chronic Lymphocytic Leukemia Treatment Product
  - 7.13.3 B-Cell Chronic Lymphocytic Leukemia Treatment Sales, Revenue, Price and Gross Margin of Noxxon Pharma AG

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT**

### **8.1 Industry Chain of B-Cell Chronic Lymphocytic Leukemia Treatment**



8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF B-CELL CHRONIC LYMPHOCYtic LEUKEMIA TREATMENT**

9.1 Cost Structure Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment

9.2 Raw Materials Cost Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment

9.3 Labor Cost Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment

9.4 Manufacturing Expenses Analysis of B-Cell Chronic Lymphocytic Leukemia Treatment

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF B-CELL CHRONIC LYMPHOCYtic LEUKEMIA TREATMENT**

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

## I would like to order

Product name: B-Cell Chronic Lymphocytic Leukemia Treatment -United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BFE4005F637MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BFE4005F637MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

